BRD4 and familial pancreatic carcinoma: The in vivo loss of KDM6A enhances gender-specific squamous-like pancreatic cancer, as an X-chromosomal gene via super-enhancer activation can be targeted with a BET inhibitor [48] via KDM6A loss-regulated BRD4 function.